BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Juno Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Juno Therapeutics\, Inc.'s drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06615479-3253@assetmemo.bio
DTSTAMP:20261121T010133Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Arlocabtagene autoleucel: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Arlocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy: 
 A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard R
 egimens in Adult Participants With Relapsed or Refractory and Lenalidomide
 -exposed Multiple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion
 : 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 rlocabtagene-autoleucel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06615479
URL:https://assetmemo.bio/drug/arlocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
